In view of that, clinical trials aiming at understanding AD mechanisms and testing AD‐modifying drugs often focus on mild cognitive impairment (MCI) individuals who show evidence of amyloid and/or tau positivity (Cummings et al. 2016; Dubois et al. 2014; Sperling et al. 2014). The gene discussed is MAPT; the disease is Alzheimer disease.